Amarin Corp Plc (AMRN)

[Whalatane]

Pdude. Understand that if Vascepa is ( as example ) $300 a month retail in the US it will cost… because of the exchange rate … about $450 Aussie dollars a month in Australia.

AMRN needs to get a reimbursement deal they can make $ on in the major EU markets
The one trial that can help them do that is Gr8 results from the CV portion of MITIGATE due in early / mid 2023

Yes these are exploratory endpoints. If the MITIGATE PI’s use Total Events analysis the event lines should clearly diverge in early 2023 …. Chk poster Laurent’s posts

If these results confirm the US portion of the R-It results …it strengthens the ‘ level of evidence’ and AMRN can resubmit to the German health dept plus others in the EU .

Kiwi